Skip navigation

A trial looking at ovarian protection for premenopausal women having chemotherapy for breast cancer (OPTION)

Please note this trial is no longer recruiting patients.

This trial is trying to find out if it is possible to protect the ovaries, and so prevent early menopause, in women having chemotherapy for breast cancer.

Doctors often treat breast cancer with chemotherapy. But chemotherapy damages the ovaries in up to 8 out of 10 women (80%) who have not been through the menopause (are premenopausal). This damage can cause premature menopause. This can be distressing, and can also lead to premature osteoporosis.

Goserelin (Zoladex) is a type of hormone therapy that usually stops the ovaries working. Doctors hope that if they can stop ovaries working while women have chemotherapy, the chemotherapy will be less likely to damage their ovaries. They hope that this will help to prevent premature menopause, but they are not sure yet how well this will work.

The aim of this trial is to see is goserelin can help prevent early menopause caused by chemotherapy.

Recruitment

Start 26/08/2004
End 31/12/2009

Phase

Phase 3

Who can enter

You can enter this trial if you

You cannot enter this trial if you

Trial design

This is a randomised trial. It will recruit 250 women into 2 groups. The women taking part will be put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.

If you are in group 1 you will have chemotherapy alone. The drugs you have will depend on your individual situation. Your doctor will talk to you about your treatment in more detail. You will have chemotherapy for between 4 and 6 months altogether.

If you are in group 2 you will have chemotherapy for about 4 to 6 months. You will also have goserelin (Zoladex) injections once every 4 weeks while you are having chemotherapy.

You will fill out a questionnaire before you start treatment and for up to 5 years afterwards. This will ask you how you have been feeling and about any side effects you have had. It is called a Quality of Life questionnaire.

Hospital visits

You will see the doctors and have some tests before you can take part in this trial. These include

  • Blood tests
  • Chest X-ray
  • Heart trace (ECG)
  • Physical examination

You may also have a bone scan to check your bone density.

You will go to the hospital every 3 or 4 weeks for chemotherapy. Exactly how often you have treatment will depend on the combination of drugs your doctor decides is best for you. You are likely to have chemotherapy for between 4 and 6 months altogether.

If you are in group 2 you will have goserelin as an injection just under the skin once a month for as long as you have chemotherapy. This can be a bit sore, so you will have a local anaesthetic to numb the skin first.

After treatment you will see the doctors every 3 months for a year, every 6 months for another year, and then every year for 3 years.

Side effects

Goserelin stops the ovaries working, so you will have some menopausal symptoms if you are in group 2. These include

  • Hot flushes
  • Mood changes

There is more information about goserelin (Zoladex) and on coping with menopausal symptoms on CancerHelp UK.

The side effects of chemotherapy will depend on the drugs you have. But the most common side effects of chemotherapy for breast cancer are

There is information about the side effects of specific chemotherapy drugs on CancerHelp UK.

Location of trial

CLOSED

For more information

The Information Nurses
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD

Tel: 0808 800 4040
Email: cancer.info@cancer.org.uk

Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you must go through your own doctor.

Chief Investigator

Professor Rob Leonard

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
National Cancer Research Network (NCRN)